### Effectiveness of mRNA-1273 against SARS-CoV-2 omicron and delta variants Supplementary Tables

**Authors:** Hung Fu Tseng, PhD,<sup>1,2,\*</sup> Bradley K. Ackerson, MD,<sup>1</sup> Yi Luo, PhD,<sup>1</sup> Lina S. Sy, MPH,<sup>1</sup> Carla A. Talarico, PhD,<sup>3</sup> Yun Tian, MS,<sup>1</sup> Katia J. Bruxvoort, PhD,<sup>4</sup> Julia E. Tubert, MPH,<sup>1</sup> Ana Florea, PhD,<sup>1</sup> Jennifer H. Ku, PhD,<sup>1</sup> Gina S. Lee, MPH,<sup>1</sup> Soon Kyu Choi, MPH,<sup>1</sup> Harpreet S. Takhar, MPH,<sup>1</sup> Michael Aragones, MD,<sup>1</sup> Lei Qian, PhD<sup>1</sup>

**Affiliations:** <sup>1</sup>Department of Research and Evaluation, Kaiser Permanente Southern California, 100 S. Los Robles Ave., Pasadena, CA, 91101, USA; <sup>2</sup>Department of Health Systems Science, Kaiser Permanente Bernard J. Tyson School of Medicine, 98 S. Los Robles Ave., Pasadena, CA, 91101, USA; <sup>3</sup>Moderna Inc., 200 Technology Square, Cambridge, MA, 02139, USA; <sup>4</sup>Department of Epidemiology, University of Alabama at Birmingham, 1665 University Blvd., Birmingham, AL, 35233, USA

#### Contents

Supplementary Table 1. Characteristics of SARS-CoV-2 cases and controls, by variant (1-dose analysis)	4
Supplementary Table 2. Full model for 1-dose VE against delta variant infection	7
Supplementary Table 3. Full model for 1-dose VE against omicron variant infection	8
Supplementary Table 4. Full model for 2-dose VE against delta variant infection	9
Supplementary Table 5. Full model for 2-dose VE against delta variant infection by time since vaccination	10
Supplementary Table 6. Full model for 2-dose VE against omicron variant infection	11
Supplementary Table 7. Full model for 2-dose VE against omicron variant infection by time since vaccination	12
Supplementary Table 8. Full model for 3-dose VE against delta variant infection	13
Supplementary Table 9. Full model for 3-dose VE against delta variant infection by time since vaccination	14
Supplementary Table 10. Full model for 3-dose VE against omicron variant infection	15
Supplementary Table 11. Full model for 3-dose VE against omicron variant infection by time since vaccination	16
Supplementary Table 12. Full model for 3-dose VE against delta variant infection by time since vaccination (excluding immunocompromised population)	17
Supplementary Table 13. Full model for 3-dose VE against omicron variant infection by time since vaccination (excluding immunocompromised population)	18
Supplementary Table 14. Full model for 1-dose VE against delta variant hospitalization	19
Supplementary Table 15. Full model for 2-dose VE against delta variant hospitalization	20
Supplementary Table 16. Full model for 2-dose VE against omicron variant hospitalization	21
Supplementary Table 17. Full model for 3-dose VE against delta variant hospitalization	22
Supplementary Table 18. Full model for 3-dose VE against omicron variant hospitalization	23
Supplementary Table 19. Full model for 3-dose VE against delta variant infection (subgroup of age<65)	24
Supplementary Table 20. Full model for 3-dose VE against delta variant infection (subgroup of age≥6	,
Supplementary Table 21. Full model for 3-dose VE against delta variant infection (subgroup of femal	,
Supplementary Table 22. Full model for 3-dose VE against delta variant infection (subgroup of male)	)27
Supplementary Table 23. Full model for 3-dose VE against delta variant infection (subgroup of Hispanic)	28
Supplementary Table 24. Full model for 3-dose VE against delta variant infection (subgroup of Non-Hispanic and others)	29

Supplementary Table 25. Full model for 3-dose VE against delta variant infection (subgroup of immunocompromised population)	30
Supplementary Table 26. Full model for 3-dose VE against delta variant infection (subgroup of non-immunocompromised)	31
Supplementary Table 27. Full model for 3-dose VE against omicron variant infection (subgroup of age<65)	32
Supplementary Table 28. Full model for 3-dose VE against omicron variant infection (subgroup of age≥65)	33
Supplementary Table 29. Full model for 3-dose VE against omicron variant infection (subgroup of female)	34
Supplementary Table 30. Full model for 3-dose VE against omicron variant infection (subgroup of ma	
Supplementary Table 31. Full model for 3-dose VE against omicron variant infection (subgroup of Hispanic)	36
Supplementary Table 32. Full model for 3-dose VE against omicron variant infection (subgroup of No Hispanic and others)	
Supplementary Table 33. Full model for 3-dose VE against omicron variant infection (subgroup of immunocompromised population)	38
Supplementary Table 34. Full model for 3-dose VE against omicron variant infection (subgroup of no immunocompromised)	
Supplementary Table 35. Full model for 3-dose VE against omicron variant infection among individual without COVID-19 history, age<65	
Supplementary Table 36. Full model for 3-dose VE against omicron variant infection among individual without COVID-19 history, age≥65	
, <del>,</del>	

## Supplementary Table 1. Characteristics of SARS-CoV-2 cases and controls, by variant (1-dose analysis)

		Delta			Omicron	
	Test Positive	Test Negative		Test Positive	Test Negative	
	Cases	Controls	p-value/ASD	Cases	Controls	p-value/ASD
	N=2942	N=5884		N=8947	N=17894	
Age at specimen collection date,	years		0.91 / 0.01			<0.01 / 0.04
mean (sd)	41.24 (14.29)	41.33 (14.36)		37.40 (13.06)	37.92 (13.25)	
median	39	39		35	36	
Q1, Q3	31, 51	31, 51		27, 46	28, 46	
min, max	18, 90	18, 101		18, 93	18, 96	
Age at specimen collection date,	years, n (%)		N/A			N/A
18-44	1844 (62.7%)	3688 (62.7%)		6477 (72.4%)	12954 (72.4%)	
45-64	904 (30.7%)	1808 (30.7%)		2188 (24.5%)	4376 (24.5%)	
65-74	153 (5.2%)	306 (5.2%)		238 (2.7%)	476 (2.7%)	
≥75	41 (1.4%)	82 (1.4%)		44 (0.5%)	88 (0.5%)	
Sex, n (%)			N/A			N/A
Female	1550 (52.7%)	3100 (52.7%)		4996 (55.8%)	9992 (55.8%)	
Male	1392 (47.3%)	2784 (47.3%)		3951 (44.2%)	7902 (44.2%)	
Race/Ethnicity, n (%)			N/A			N/A
Non-Hispanic White	1159 (39.4%)	2318 (39.4%)		2526 (28.2%)	5052 (28.2%)	
Non-Hispanic Black	181 (6.2%)	362 (6.2%)		961 (10.7%)	1922 (10.7%)	
Hispanic	1265 (43.0%)	2530 (43.0%)		4319 (48.3%)	8638 (48.3%)	
Non-Hispanic Asian	97 (3.3%)	194 (3.3%)		387 (4.3%)	774 (4.3%)	
Other/Unknown	240 (8.2%)	480 (8.2%)		754 (8.4%)	1508 (8.4%)	
Body mass index <sup>b</sup> , n (%)			<0.01 / 0.15			<0.01 / 0.08
<18.5	20 (0.7%)	71 (1.2%)		105 (1.2%)	224 (1.3%)	
18.5 - <25	545 (18.5%)	1273 (21.6%)		1730 (19.3%)	3645 (20.4%)	
25 - <30	740 (25.2%)	1591 (27.0%)		2377 (26.6%)	4609 (25.8%)	
30 - <35	590 (20.1%)	1084 (18.4%)		1655 (18.5%)	3503 (19.6%)	
35 - <40	295 (10.0%)	607 (10.3%)		837 (9.4%)	1806 (10.1%)	
40 - <45	117 (4.0%)	247 (4.2%)		393 (4.4%)	795 (4.4%)	
≥45	66 (2.2%)	147 (2.5%)		245 (2.7%)	539 (3.0%)	
Unknown	569 (19.3%)	864 (14.7%)		1605 (17.9%)	2773 (15.5%)	
Smoking <sup>b</sup> , n (%)			<0.01 / 0.12			<0.01 / 0.07
No	1981 (67.3%)	4103 (69.7%)		6375 (71.3%)	12709 (71.0%)	
Yes	484 (16.5%)	1068 (18.2%)		1268 (14.2%)	2883 (16.1%)	
Unknown	477 (16.2%)	713 (12.1%)		1304 (14.6%)	2302 (12.9%)	
Charlson comorbidity score <sup>a</sup> , n (%	6)		0.01 / 0.07			<0.01 / 0.13
0	2443 (83.0%)	4760 (80.9%)	•	7721 (86.3%)	14725 (82.3%)	•
1	316 (10.7%)	652 (11.1%)		866 (9.7%)	2001 (11.2%)	
≥2	183 (6.2%)	472 (8.0%)		360 (4.0%)	1168 (6.5%)	
<del></del>	(0/0)	= (0.0,0)		(/ )	(0.0,0)	

Frailty index <sup>a</sup> , n (%)			<0.01 / 0.17			<0.01 / 0.13
Quartile 1	731 (24.8%)	1474 (25.1%)		2163 (24.2%)	4258 (23.8%)	
Quartile 2	856 (29.1%)	1350 (22.9%)		2571 (28.7%)	4424 (24.7%)	
Quartile 3	728 (24.7%)	1481 (25.2%)		2272 (25.4%)	4442 (24.8%)	
Quartile 4 (most frail)	627 (21.3%)	1579 (26.8%)		1941 (21.7%)	4770 (26.7%)	
Chronic diseases <sup>a</sup> , n (%)						
Kidney disease	41 (1.4%)	117 (2.0%)	0.05 / 0.05	62 (0.7%)	289 (1.6%)	<0.01 / 0.09
Heart disease	34 (1.2%)	108 (1.8%)	0.02 / 0.06	59 (0.7%)	232 (1.3%)	<0.01 / 0.06
Lung disease	193 (6.6%)	461 (7.8%)	0.03 / 0.05	531 (5.9%)	1393 (7.8%)	<0.01 / 0.07
Liver disease	68 (2.3%)	162 (2.8%)	0.22 / 0.03	175 (2.0%)	483 (2.7%)	<0.01 / 0.05
Diabetes	170 (5.8%)	386 (6.6%)	0.15 / 0.03	398 (4.4%)	1064 (5.9%)	<0.01 / 0.07
Immunocompromised, n (%)	32 (1.1%)	173 (2.9%)	<0.01 / 0.13	131 (1.5%)	488 (2.7%)	<0.01 / 0.09
HIV/AIDS Leukemia/lymphoma, congenital and other immunodeficiencies,	2	4		12	30	
asplenia/hyposplenia Hematopoietic stem cell transplantation/ organ	12	62		44	150	
transplant Immunosuppressant	2	6		7	29	
medications	18	120		83	342	
Autoimmune conditions <sup>a</sup> , n (%)	55 (1.9%)	160 (2.7%)	0.01 / 0.06	146 (1.6%)	373 (2.1%)	0.01 / 0.03
Rheumatoid arthritis Inflammatory bowel	13	54		49	165	
disease Psoriasis and psoriatic	15	50		42	92	
arthritis	23	53		44	94	
Multiple sclerosis	4	8		12	24	
Systemic lupus erythematosus Pregnant at specimen collection	3	12		19	55	
date, n (%)	57 (1.9%)	203 (3.5%)	<0.01 / 0.09	195 (2.2%)	774 (4.3%)	<0.01 / 0.12
1st trimester	16	28		33	80	
2nd trimester	19	48		69	174	
3rd trimester	22	127		93	520	
History of COVID-19 <sup>c</sup> , n (%) History of SARS-CoV-2 molecular	79 (2.7%)	1354 (23.0%)	<0.01 / 0.64	1622 (18.1%)	4473 (25.0%)	<0.01 / 0.17
test <sup>c</sup> , n (%)	1886 (64.1%)	4684 (79.6%)	<0.01 / 0.35	6563 (73.4%)	13347 (74.6%)	0.03 / 0.03
Number of outpatient and virtual v	visits <sup>a</sup> , n (%)		<0.01 / 0.29			<0.01 / 0.19
0	460 (15.6%)	586 (10.0%)		1196 (13.4%)	1920 (10.7%)	
1-4	1123 (38.2%)	1823 (31.0%)		3460 (38.7%)	5990 (33.5%)	
5-10	711 (24.2%)	1593 (27.1%)		2275 (25.4%)	4596 (25.7%)	
≥11	648 (22.0%)	1882 (32.0%)		2016 (22.5%)	5388 (30.1%)	
Number of Emergency Department visits <sup>a</sup> , n (%)			<0.01 / 0.18			<0.01 / 0.14
0	2513 (85.4%)	4642 (78.9%)		7449 (83.3%)	14106 (78.8%)	
1	308 (10.5%)	830 (14.1%)		1111 (12.4%)	2506 (14.0%)	

≥2	121 (4.1%)	412 (7.0%)		387 (4.3%)	1282 (7.2%)	
Number of hospitalizations <sup>a</sup> , n (%)			0.02 / 0.07			<0.01 / 0.11
0	2797 (95.1%)	5512 (93.7%)		8561 (95.7%)	16710 (93.4%)	
1	118 (4.0%)	285 (4.8%)		340 (3.8%)	948 (5.3%)	
≥2	27 (0.9%)	87 (1.5%)		46 (0.5%)	236 (1.3%)	
Preventive carea, n(%)	1355 (46.1%)	2965 (50.4%)	<0.01 / 0.09	3971 (44.4%)	8578 (47.9%)	<0.01 / 0.07
Medicaid, n (%)	303 (10.3%)	684 (11.6%)	0.06 / 0.04	1077 (12.0%)	2495 (13.9%)	<0.01 / 0.06
Neighborhood median household	income, n(%)		0.04 / 0.07			<0.01 / 0.06
< \$40,000	127 (4.3%)	273 (4.6%)		387 (4.3%)	948 (5.3%)	
\$40,000-\$59,999	490 (16.7%)	1132 (19.2%)		1789 (20.0%)	3820 (21.3%)	
\$60,000-\$79,999	799 (27.2%)	1515 (25.7%)		2447 (27.3%)	4724 (26.4%)	
\$80,000+	1524 (51.8%)	2959 (50.3%)		4307 (48.1%)	8373 (46.8%)	
Unknown	2 (0.1%)	5 (0.1%)		17 (0.2%)	29 (0.2%)	
KPSC physician/employee, n (%)	75 (2.5%)	533 (9.1%)	<0.01 / 0.28	275 (3.1%)	466 (2.6%)	0.03 / 0.03
Specimen type, n (%) Nasopharyngeal/oropharyn			<0.01 / 0.55			<0.01 / 0.21
geal swab	2541 (86.4%)	3724 (63.3%)		7599 (84.9%)	13730 (76.7%)	
Saliva	401 (13.6%)	2160 (36.7%)		1348 (15.1%)	4164 (23.3%)	

<sup>&</sup>lt;sup>a</sup> Defined in the one year prior to specimen collection date

Medical center area not shown. There were differences in the distribution of the vaccinated and unvaccinated individuals across the 19 medical center areas.

N/A = not applicable

<sup>&</sup>lt;sup>b</sup> Defined in the two years prior to specimen collection date

<sup>&</sup>lt;sup>c</sup> Defined based on all available medical records from March 1, 2020 to specimen collection date

### Supplementary Table 2. Full model for 1-dose VE against delta variant infection

Odds Ratio Estimates				
	Point	95% Wald	Confidence	
Effect	Estimate	Inte	erval	
Vaccination status, Vaccinated vs Unvaccinated	0.433	0.316	0.593	
History of SARS-CoV-2 molecular test, No vs Yes	1.347	1.201	1.512	
Preventive Care, No vs Yes	1.12	0.995	1.261	
Number of outpatient and virtual visits, 0 vs >=11	1.581	1.236	2.022	
Number of outpatient and virtual visits, 1-4 vs >=11	1.443	1.236	1.686	
Number of outpatient and virtual visits, 5-10 vs >=11	1.151	0.991	1.336	
Obese, No vs Yes	0.857	0.764	0.961	
Obese, Unknown vs Yes	0.914	0.768	1.088	
Charlson comorbidity score, 0 vs >=2	0.969	0.766	1.226	
Charlson comorbidity score, 1 vs >=2	1.117	0.866	1.443	
Frailty, Quartile 1 vs Quartile 4	1.227	1.04	1.448	
Frailty, Quartile 2 vs Quartile 4	1.212	0.999	1.469	
Frailty, Quartile 3 vs Quartile 4	1.2	1.023	1.407	
Specimen type, Nasopharyngeal/oropharyngeal swab vs Saliva	3.657	3.206	4.172	
Immunocompromised status, No vs Yes	2.479	1.622	3.789	
History of COVID-19 diagnosis, No vs Yes	10.064	7.838	12.922	

### Supplementary Table 3. Full model for 1-dose VE against omicron variant infection

Odds Ratio Estimates					
	Point		l Confidence		
Effect	Estimate	Int	erval		
Vaccination status, Vaccinated vs Unvaccinated	0.796	0.7	0.905		
History of SARS-CoV-2 molecular test, No vs Yes	0.849	0.797	0.904		
Preventive Care, No vs Yes	1.067	1.004	1.134		
Number of outpatient and virtual visits, 0 vs >=11	1.546	1.362	1.754		
Number of outpatient and virtual visits, 1-4 vs >=11	1.438	1.328	1.558		
Number of outpatient and virtual visits, 5-10 vs >=11	1.265	1.172	1.366		
Obese, No vs Yes	1.014	0.956	1.075		
Obese, Unknown vs Yes	0.984	0.9	1.076		
Charlson comorbidity score, 0 vs >=2	1.394	1.212	1.604		
Charlson comorbidity score, 1 vs >=2	1.295	1.113	1.507		
Frailty, Quartile 1 vs Quartile 4	1.078	0.991	1.173		
Frailty, Quartile 2 vs Quartile 4	1.105	1.004	1.215		
Frailty, Quartile 3 vs Quartile 4	1.109	1.024	1.2		
Specimen type, Nasopharyngeal/oropharyngeal swab vs Saliva	1.781	1.662	1.909		
Immunocompromised status, No vs Yes	1.512	1.235	1.851		
History of COVID-19 diagnosis, No vs Yes	1.53	1.43	1.637		

### Supplementary Table 4. Full model for 2-dose VE against delta variant infection

Odds Ratio Estimates				
	Point	95% Wald	Confidence	
Effect	Estimate	Inte	erval	
Vaccination status, Vaccinated vs Unvaccinated	0.364	0.331	0.401	
History of SARS-CoV-2 molecular test, No vs Yes	1.222	1.108	1.347	
Preventive Care, No vs Yes	1.064	0.96	1.178	
Number of outpatient and virtual visits, 0 vs >=11	1.541	1.243	1.909	
Number of outpatient and virtual visits, 1-4 vs >=11	1.425	1.248	1.628	
Number of outpatient and virtual visits, 5-10 vs >=11	1.188	1.053	1.341	
Obese, No vs Yes	0.882	0.801	0.971	
Obese, Unknown vs Yes	0.913	0.784	1.063	
Charlson comorbidity score, 0 vs >=2	1.154	0.958	1.389	
Charlson comorbidity score, 1 vs >=2	1.309	1.069	1.603	
Frailty, Quartile 1 vs Quartile 4	1.209	1.049	1.394	
Frailty, Quartile 2 vs Quartile 4	1.205	1.033	1.405	
Frailty, Quartile 3 vs Quartile 4	1.173	1.025	1.341	
Specimen type, Nasopharyngeal/oropharyngeal swab vs Saliva	3.455	3.063	3.897	
Immunocompromised status, No vs Yes	1.635	1.203	2.224	
History of COVID-19 diagnosis, No vs Yes	10.112	8.142	12.558	

### Supplementary Table 5. Full model for 2-dose VE against delta variant infection by time since vaccination

Odds Ratio Estimates					
		95%	6 Wald		
Effect	Point Estimate	Confider	nce Interval		
Vaccination status, Vaccinated 14-90 days vs Unvaccinated	0.198	0.123	0.318		
Vaccination status, Vaccinated 91-180 days vs Unvaccinated	0.311	0.242	0.399		
Vaccination status, Vaccinated 181-270 days vs Unvaccinated	0.363	0.328	0.402		
Vaccination status, Vaccinated 271-365 days vs Unvaccinated	0.387	0.333	0.45		
History of SARS-CoV-2 molecular test, No vs Yes	1.23	1.12	1.352		
Preventive Care, No vs Yes	1.07	0.971	1.179		
Number of outpatient and virtual visits, 0 vs >=11	1.459	1.189	1.79		
Number of outpatient and virtual visits, 1-4 vs >=11	1.405	1.239	1.594		
Number of outpatient and virtual visits, 5-10 vs >=11	1.177	1.049	1.32		
Obese, No vs Yes	0.906	0.827	0.993		
Obese, Unknown vs Yes	0.952	0.824	1.1		
Charlson comorbidity score, 0 vs >=2	1.126	0.944	1.344		
Charlson comorbidity score, 1 vs >=2	1.235	1.02	1.497		
Frailty, Quartile 1 vs Quartile 4	1.177	1.027	1.348		
Frailty, Quartile 2 vs Quartile 4	1.15	0.993	1.332		
Frailty, Quartile 3 vs Quartile 4	1.125	0.99	1.279		
Specimen type, Nasopharyngeal/oropharyngeal swab vs Saliva	3.575	3.189	4.008		
Immunocompromised status, No vs Yes	1.731	1.293	2.317		
History of COVID-19 diagnosis, No vs Yes	9.929	8.06	12.231		
Age group, 18-44 years old vs 75 and older	0.735	0.533	1.013		
Age group, 45-64 years old vs 75 and older	0.844	0.615	1.159		
Age group, 65-74 years old vs 75 and older	0.865	0.616	1.214		
Sex, Female vs Male	1.185	1.087	1.292		
Race/ethnicity, Hispanic vs Other/Unknown	1.157	0.986	1.358		
Race/ethnicity, Non-Hispanic Asian vs Other/Unknown	1.336	1.047	1.706		
Race/ethnicity, Non-Hispanic Black vs Other/Unknown	1.039	0.829	1.303		
Race/ethnicity, Non-Hispanic White vs Other/Unknown	1.067	0.907	1.254		

### Supplementary Table 6. Full model for 2-dose VE against omicron variant infection

Odds Ratio Estimates					
	Point	95% Wald	Confidence		
Effect	Estimate	Inte	rval		
Vaccination status, Vaccinated vs Unvaccinated	0.861	0.829	0.895		
History of SARS-CoV-2 molecular test, No vs Yes	0.943	0.905	0.984		
Preventive Care, No vs Yes	1.12	1.075	1.168		
Number of outpatient and virtual visits, 0 vs >=11	1.413	1.287	1.552		
Number of outpatient and virtual visits, 1-4 vs >=11	1.379	1.305	1.457		
Number of outpatient and virtual visits, 5-10 vs >=11	1.267	1.206	1.33		
Obese, No vs Yes	0.942	0.905	0.98		
Obese, Unknown vs Yes	0.985	0.925	1.05		
Charlson comorbidity score, 0 vs >=2	1.314	1.208	1.43		
Charlson comorbidity score, 1 vs >=2	1.274	1.162	1.396		
Frailty, Quartile 1 vs Quartile 4	1.091	1.031	1.155		
Frailty, Quartile 2 vs Quartile 4	1.099	1.031	1.171		
Frailty, Quartile 3 vs Quartile 4	1.101	1.044	1.162		
Specimen type, Nasopharyngeal/oropharyngeal swab vs Saliva	1.892	1.796	1.993		
Immunocompromised status, No vs Yes	1.34	1.178	1.524		
History of COVID-19 diagnosis, No vs Yes	1.639	1.558	1.724		

### Supplementary Table 7. Full model for 2-dose VE against omicron variant infection by time since vaccination

Odds Ratio Estimates					
	95% Wald	Confidence			
Effect	Point Estimate	Inte	erval		
Vaccination status, Vaccinated 14-90 days vs Unvaccinated	0.56	0.484	0.649		
Vaccination status, Vaccinated 91-180 days vs Unvaccinated	0.765	0.7	0.836		
Vaccination status, Vaccinated 181-270 days vs Unvaccinated	0.862	0.827	0.898		
Vaccination status, Vaccinated 271-365 days vs Unvaccinated	0.941	0.89	0.996		
History of SARS-CoV-2 molecular test, No vs Yes	0.939	0.901	0.979		
Preventive Care, No vs Yes	1.129	1.083	1.177		
Number of outpatient and virtual visits, 0 vs >=11	1.396	1.271	1.532		
Number of outpatient and virtual visits, 1-4 vs >=11	1.368	1.296	1.445		
Number of outpatient and virtual visits, 5-10 vs >=11	1.26	1.2	1.322		
Obese, No vs Yes	0.94	0.904	0.978		
Obese, Unknown vs Yes	0.988	0.928	1.051		
Charlson comorbidity score, 0 vs >=2	1.312	1.206	1.428		
Charlson comorbidity score, 1 vs >=2	1.268	1.157	1.389		
Frailty, Quartile 1 vs Quartile 4	1.098	1.037	1.162		
Frailty, Quartile 2 vs Quartile 4	1.102	1.035	1.174		
Frailty, Quartile 3 vs Quartile 4	1.105	1.047	1.166		
Specimen type, Nasopharyngeal/oropharyngeal swab vs Saliva	1.897	1.801	1.998		
Immunocompromised status, No vs Yes	1.344	1.182	1.528		
History of COVID-19 diagnosis, No vs Yes	1.638	1.557	1.723		
Age group, 18-44 years old vs 75 and older	0.729	0.609	0.872		
Age group, 45-64 years old vs 75 and older	0.818	0.684	0.978		
Age group, 65-74 years old vs 75 and older	0.902	0.742	1.097		
Sex, Female vs Male	1.106	1.066	1.148		
Race/ethnicity, Hispanic vs Other/Unknown	1.067	0.999	1.14		
Race/ethnicity, Non-Hispanic Asian vs Other/Unknown	1.049	0.961	1.144		
Race/ethnicity, Non-Hispanic Black vs Other/Unknown	1.092	1.003	1.188		
Race/ethnicity, Non-Hispanic White vs Other/Unknown	1.05	0.979	1.126		

### Supplementary Table 8. Full model for 3-dose VE against delta variant infection

Odds Ratio Estimates					
	Point		Confidence		
Effect	Estimate	Int	erval		
Vaccination status, Vaccinated vs Unvaccinated	0.055	0.043	0.071		
History of SARS-CoV-2 molecular test, No vs Yes	1.391	1.226	1.578		
Preventive Care, No vs Yes	1.176	1.031	1.342		
Number of outpatient and virtual visits, 0 vs >=11	1.434	1.105	1.861		
Number of outpatient and virtual visits, 1-4 vs >=11	1.407	1.187	1.667		
Number of outpatient and virtual visits, 5-10 vs >=11	1.138	0.97	1.336		
Obese, No vs Yes	0.881	0.78	0.996		
Obese, Unknown vs Yes	0.92	0.762	1.111		
Charlson comorbidity score, 0 vs >=2	0.951	0.737	1.227		
Charlson comorbidity score, 1 vs >=2	1.216	0.921	1.606		
Frailty, Quartile 1 vs Quartile 4	1.145	0.953	1.374		
Frailty, Quartile 2 vs Quartile 4	1.042	0.852	1.275		
Frailty, Quartile 3 vs Quartile 4	1.051	0.884	1.249		
Specimen type, Nasopharyngeal/oropharyngeal swab vs Saliva	3.673	3.191	4.229		
Immunocompromised status, No vs Yes	1.935	1.298	2.884		
History of COVID-19 diagnosis, No vs Yes	7.863	6.188	9.992		

### Supplementary Table 9. Full model for 3-dose VE against delta variant infection by time since vaccination

Odds Ratio Estimates			
	95% W	/ald Confidence	
Effect	Point Estimate		Interval
Vaccination status, Vaccinated 14-60 days vs Unvaccinated	0.063	0.051	0.078
Vaccination status, Vaccinated 61-365 days vs Unvaccinated	0.14	0.089	0.219
History of SARS-CoV-2 molecular test, No vs Yes	1.4	1.246	1.572
Preventive Care, No vs Yes	1.154	1.022	1.303
Number of outpatient and virtual visits, 0 vs >=11	1.453	1.14	1.851
Number of outpatient and virtual visits, 1-4 vs >=11	1.414	1.209	1.653
Number of outpatient and virtual visits, 5-10 vs >=11	1.175	1.013	1.362
Obese, No vs Yes	0.869	0.777	0.973
Obese, Unknown vs Yes	0.947	0.797	1.125
Charlson comorbidity score, 0 vs >=2	0.972	0.77	1.226
Charlson comorbidity score, 1 vs >=2	1.214	0.943	1.561
Frailty, Quartile 1 vs Quartile 4	1.151	0.973	1.362
Frailty, Quartile 2 vs Quartile 4	1.07	0.889	1.289
Frailty, Quartile 3 vs Quartile 4	1.06	0.905	1.242
Specimen type, Nasopharyngeal/oropharyngeal swab vs Saliva	3.804	3.35	4.319
Immunocompromised status, No vs Yes	1.982	1.376	2.855
History of COVID-19 diagnosis, No vs Yes	8.137	6.498	10.191
Age group, 18-44 years old vs 75 and older	0.317	0.203	0.494
Age group, 45-64 years old vs 75 and older	0.432	0.278	0.669
Age group, 65-74 years old vs 75 and older	0.763	0.479	1.216
Sex, Female vs Male	1.26	1.132	1.402
Race/ethnicity, Hispanic vs Other/Unknown	0.971	0.801	1.178
Race/ethnicity, Non-Hispanic Asian vs Other/Unknown	1.964	1.414	2.726
Race/ethnicity, Non-Hispanic Black vs Other/Unknown	0.906	0.694	1.184
Race/ethnicity, Non-Hispanic White vs Other/Unknown	1.058	0.87	1.287

### Supplementary Table 10. Full model for 3-dose VE against omicron variant infection

Odds Ratio Estimates			
	Point	95% Wald	Confidence
Effect	Estimate	Inte	erval
Vaccination status, Vaccinated vs Unvaccinated	0.3	0.281	0.32
History of SARS-CoV-2 molecular test, No vs Yes	0.917	0.865	0.972
Preventive Care, No vs Yes	1.073	1.011	1.14
Number of outpatient and virtual visits, 0 vs >=11	1.566	1.384	1.772
Number of outpatient and virtual visits, 1-4 vs >=11	1.377	1.278	1.484
Number of outpatient and virtual visits, 5-10 vs >=11	1.208	1.13	1.291
Obese, No vs Yes	1.019	0.965	1.076
Obese, Unknown vs Yes	0.984	0.901	1.074
Charlson comorbidity score, 0 vs >=2	1.092	0.981	1.216
Charlson comorbidity score, 1 vs >=2	1.003	0.894	1.125
Frailty, Quartile 1 vs Quartile 4	1.053	0.973	1.141
Frailty, Quartile 2 vs Quartile 4	1.053	0.966	1.148
Frailty, Quartile 3 vs Quartile 4	1.091	1.012	1.175
Specimen type, Nasopharyngeal/oropharyngeal swab vs Saliva	1.661	1.558	1.771
Immunocompromised status, No vs Yes	1.105	0.95	1.285
History of COVID-19 diagnosis, No vs Yes	1.469	1.373	1.572

### Supplementary Table 11. Full model for 3-dose VE against omicron variant infection by time since vaccination

Odds Ratio Estimates			
		95% Wald (	Confidence
Effect	Point Estimate	Inte	rval
Vaccination status, Vaccinated 14-60 days vs Unvaccinated	0.284	0.266	0.303
Vaccination status, Vaccinated 61-365 days vs Unvaccinated	0.526	0.465	0.595
History of SARS-CoV-2 molecular test, No vs Yes	0.916	0.865	0.97
Preventive Care, No vs Yes	1.077	1.015	1.143
Number of outpatient and virtual visits, 0 vs >=11	1.57	1.392	1.772
Number of outpatient and virtual visits, 1-4 vs >=11	1.387	1.289	1.492
Number of outpatient and virtual visits, 5-10 vs >=11	1.227	1.149	1.31
Obese, No vs Yes	1.013	0.961	1.068
Obese, Unknown vs Yes	0.975	0.894	1.062
Charlson comorbidity score, 0 vs >=2	1.119	1.007	1.244
Charlson comorbidity score, 1 vs >=2	1.021	0.911	1.143
Frailty, Quartile 1 vs Quartile 4	1.063	0.983	1.149
Frailty, Quartile 2 vs Quartile 4	1.061	0.974	1.155
Frailty, Quartile 3 vs Quartile 4	1.089	1.013	1.172
Specimen type, Nasopharyngeal/oropharyngeal swab vs Saliva	1.685	1.582	1.794
Immunocompromised status, No vs Yes	1.217	1.048	1.413
History of COVID-19 diagnosis, No vs Yes	1.477	1.382	1.579
Age group, 18-44 years old vs 75 and older	0.42	0.352	0.502
Age group, 45-64 years old vs 75 and older	0.599	0.503	0.714
Age group, 65-74 years old vs 75 and older	0.887	0.736	1.069
Sex, Female vs Male	1.135	1.079	1.193
Race/ethnicity, Hispanic vs Other/Unknown	0.977	0.891	1.071
Race/ethnicity, Non-Hispanic Asian vs Other/Unknown	1.443	1.274	1.635
Race/ethnicity, Non-Hispanic Black vs Other/Unknown	0.939	0.839	1.052
Race/ethnicity, Non-Hispanic White vs Other/Unknown	1.015	0.921	1.117

## Supplementary Table 12. Full model for 3-dose VE against delta variant infection by time since vaccination (excluding immunocompromised population)

Odds Ratio Estimates				
95% Wald Confidence				
Effect	Point Estimate	Interval		
Vaccination status, Vaccinated 14-60 days vs Unvaccinated	0.058	0.047	0.073	
Vaccination status, Vaccinated 61-365 days vs Unvaccinated	0.119	0.071	0.198	
History of SARS-CoV-2 molecular test, No vs Yes	1.388	1.234	1.561	
Preventive Care, No vs Yes	1.144	1.012	1.293	
Number of outpatient and virtual visits, 0 vs >=11	1.467	1.148	1.876	
Number of outpatient and virtual visits, 1-4 vs >=11	1.429	1.22	1.674	
Number of outpatient and virtual visits, 5-10 vs >=11	1.193	1.026	1.386	
Obese, No vs Yes	0.861	0.768	0.965	
Obese, Unknown vs Yes	0.933	0.784	1.109	
Charlson comorbidity score, 0 vs >=2	0.945	0.742	1.204	
Charlson comorbidity score, 1 vs >=2	1.159	0.891	1.507	
Frailty, Quartile 1 vs Quartile 4	1.157	0.977	1.37	
Frailty, Quartile 2 vs Quartile 4	1.093	0.904	1.32	
Frailty, Quartile 3 vs Quartile 4	1.096	0.933	1.287	
Specimen type, Nasopharyngeal/oropharyngeal swab vs Saliva	3.79	3.335	4.307	
History of COVID-19 diagnosis, No vs Yes	8.248	6.569	10.356	
Age group, 18-44 years old vs 75 and older	0.308	0.195	0.489	
Age group, 45-64 years old vs 75 and older	0.419	0.266	0.661	
Age group, 65-74 years old vs 75 and older	0.786	0.485	1.275	
Sex, Female vs Male	1.264	1.134	1.408	
Race/ethnicity, Hispanic vs Other/Unknown	0.97	0.799	1.179	
Race/ethnicity, Non-Hispanic Asian vs Other/Unknown	1.96	1.404	2.735	
Race/ethnicity, Non-Hispanic Black vs Other/Unknown	0.881	0.673	1.154	
Race/ethnicity, Non-Hispanic White vs Other/Unknown	1.07	0.879	1.304	

### Supplementary Table 13. Full model for 3-dose VE against omicron variant infection by time since vaccination (excluding immunocompromised population)

		050/ 14/-1-1-0	<b></b>
Effect	Point Estimate	95% Wald C Inter	
Vaccination status, Vaccinated 14-60 days vs Unvaccinated	0.279	0.261	0.298
Vaccination status, Vaccinated 61-365 days vs Unvaccinated	0.488	0.427	0.558
History of SARS-CoV-2 molecular test, No vs Yes	0.91	0.859	0.964
Preventive Care, No vs Yes	1.067	1.004	1.133
Number of outpatient and virtual visits, 0 vs >=11	1.566	1.385	1.769
Number of outpatient and virtual visits, 1-4 vs >=11	1.381	1.282	1.487
Number of outpatient and virtual visits, 5-10 vs >=11	1.217	1.138	1.301
Obese, No vs Yes	1.015	0.962	1.071
Obese, Unknown vs Yes	0.978	0.896	1.066
Charlson comorbidity score, 0 vs >=2	1.136	1.016	1.269
Charlson comorbidity score, 1 vs >=2	1.042	0.925	1.174
Frailty, Quartile 1 vs Quartile 4	1.065	0.985	1.153
Frailty, Quartile 2 vs Quartile 4	1.066	0.978	1.163
Frailty, Quartile 3 vs Quartile 4	1.089	1.011	1.172
Specimen type, Nasopharyngeal/oropharyngeal swab vs Saliva	1.704	1.599	1.817
History of COVID-19 diagnosis, No vs Yes	1.478	1.382	1.581
Age group, 18-44 years old vs 75 and older	0.399	0.332	0.481
Age group, 45-64 years old vs 75 and older	0.568	0.473	0.683
Age group, 65-74 years old vs 75 and older	0.854	0.704	1.037
Sex, Female vs Male	1.139	1.083	1.199
Race/ethnicity, Hispanic vs Other/Unknown	0.973	0.887	1.069
Race/ethnicity, Non-Hispanic Asian vs Other/Unknown	1.461	1.287	1.658
Race/ethnicity, Non-Hispanic Black vs Other/Unknown	0.937	0.836	1.051
Race/ethnicity, Non-Hispanic White vs Other/Unknown	1.015	0.92	1.118

### Supplementary Table 14. Full model for 1-dose VE against delta variant hospitalization

Effect	Point Estimate	55,5 114.4	Confidence erval
Vaccination status, Vaccinated vs Unvaccinated	0.288	0.026	3.194
History of SARS-CoV-2 molecular test, No vs Yes	1.59	0.795	3.182
Preventive Care, No vs Yes	2.393	1.041	5.502
Obese, No vs Yes	0.166	0.066	0.413
Obese, Unknown vs Yes	0.268	0.082	0.882
Charlson comorbidity score, 0 vs >=2	0.592	0.237	1.481
Charlson comorbidity score, 1 vs >=2	0.902	0.282	2.88
History of COVID-19 diagnosis, No vs Yes	10.386	2.246	48.021

### Supplementary Table 15. Full model for 2-dose VE against delta variant hospitalization

Effect	Point Estimate		d Confidence terval
Vaccination status, Vaccinated vs Unvaccinated	0.01	0.001	0.067
History of SARS-CoV-2 molecular test, No vs Yes	0.734	0.267	2.02
Preventive Care, No vs Yes	4.08	1.353	12.307
Obese, No vs Yes	0.092	0.024	0.349
Obese, Unknown vs Yes	0.546	0.132	2.265
Charlson comorbidity score, 0 vs >=2	0.219	0.039	1.224
Charlson comorbidity score, 1 vs >=2	1.259	0.197	8.031
History of COVID-19 diagnosis, No vs Yes	18.718	2.917	120.099

### Supplementary Table 16. Full model for 2-dose VE against omicron variant hospitalization

Effect	Point Estimate	95% Wald Confidence Interval	
Vaccination status, Vaccinated vs Unvaccinated	0.155	0.031	0.77
History of SARS-CoV-2 molecular test, No vs Yes	4.677	0.635	34.442
Preventive Care, No vs Yes	0.717	0.146	3.515
Charlson comorbidity score, 0 vs >=2	0.902	0.083	9.842
Charlson comorbidity score, 1 vs >=2	3.359	0.237	47.543
Immunocompromised status, No vs Yes	0.175	0.006	5.289
History of COVID-19 diagnosis, No vs Yes	2.364	0.172	32.54

#### Supplementary Table 17. Full model for 3-dose VE against delta variant hospitalization

	Point		Confidence
Effect	Estimate	Inte	erval
Vaccination status, Vaccinated vs Unvaccinated	0.003	<0.001	0.035
History of SARS-CoV-2 molecular test, No vs Yes	1.738	0.79	3.825
Preventive Care, No vs Yes	1.715	0.759	3.875
Obese, No vs Yes	0.322	0.136	0.762
Obese, Unknown vs Yes	0.418	0.14	1.249
Charlson comorbidity score, 0 vs >=2	0.313	0.105	0.931
Charlson comorbidity score, 1 vs >=2	0.479	0.131	1.753
History of COVID-19 diagnosis, No vs Yes	8.736	1.711	44.601
Age group, 18-44 years old vs 75 and older	0.202	0.031	1.312
Age group, 45-64 years old vs 75 and older	0.23	0.039	1.363
Age group, 65-74 years old vs 75 and older	1.484	0.177	12.452
Sex, Female vs Male	1.157	0.53	2.524
Race/ethnicity, Hispanic vs Other/Unknown	0.817	0.202	3.304
Race/ethnicity, Non-Hispanic Asian vs Other/Unknown	1.146	0.138	9.498
Race/ethnicity, Non-Hispanic Black vs Other/Unknown	1.428	0.254	8.024
Race/ethnicity, Non-Hispanic White vs Other/Unknown	0.858	0.202	3.638

### Supplementary Table 18. Full model for 3-dose VE against omicron variant hospitalization

Effect	Point Estimate		ıld Confidence nterval	
Vaccination status, Vaccinated vs Unvaccinated	0.008	<0.001	0.237	
History of SARS-CoV-2 molecular test, No vs Yes	0.473	0.059	3.765	
Preventive Care, No vs Yes	1.008	0.075	13.531	
Charlson comorbidity score, 0 vs >=2	0.033	0.002	0.725	
Charlson comorbidity score, 1 vs >=2	0.765	0.02	29.284	
Immunocompromised status, No vs Yes	0.261	0.007	9.422	
Age group, 18-44 years old vs 75 and older	0.862	0.052	14.438	
Age group, 45-64 years old vs 75 and older	2.605	0.099	68.699	
Age group, 65-74 years old vs 75 and older	1.62	0.078	33.492	
Sex, Female vs Male	0.216	0.02	2.356	
Race/ethnicity, Hispanic vs Non-Hispanic White	3.084	0.2	47.486	
Race/ethnicity, Non-Hispanic Asian vs Non-Hispanic White	5.291	0.124	224.949	
Race/ethnicity, Non-Hispanic Black vs Non-Hispanic White	0.435	0.024	7.917	

## Supplementary Table 19. Full model for 3-dose VE against delta variant infection (subgroup of age<65)

Odds Ratio Estimates			
Effect	Point Estimate	95% Wald (	
Vaccination status, Vaccinated vs Unvaccinated	0.057	0.043	0.075
History of SARS-CoV-2 molecular test, No vs Yes	1.416	1.243	1.614
Preventive Care, No vs Yes	1.18	1.032	1.349
Number of outpatient and virtual visits, 0 vs >=11	1.42	1.084	1.86
Number of outpatient and virtual visits, 1-4 vs >=11	1.412	1.186	1.682
Number of outpatient and virtual visits, 5-10 vs >=11	1.158	0.981	1.368
Obese, No vs Yes	0.895	0.788	1.016
Obese, Unknown vs Yes	0.927	0.765	1.123
Charlson comorbidity score, 0 vs >=2	0.939	0.707	1.246
Charlson comorbidity score, 1 vs >=2	1.186	0.866	1.623
Frailty, Quartile 1 vs Quartile 4	1.176	0.981	1.41
Frailty, Quartile 2 vs Quartile 4	1.1	0.893	1.356
Frailty, Quartile 3 vs Quartile 4	1.096	0.921	1.306
Specimen type, Nasopharyngeal/oropharyngeal swab vs Saliva	3.833	3.315	4.432
Immunocompromised status, No vs Yes	1.754	1.14	2.699
History of COVID-19 diagnosis, No vs Yes	7.724	6.063	9.84

# Supplementary Table 20. Full model for 3-dose VE against delta variant infection (subgroup of age≥65)

Odds Ratio Estimates			
Effect	Point Estimate	95% Wald (	
Vaccination status, Vaccinated vs Unvaccinated	0.04	0.021	0.077
History of SARS-CoV-2 molecular test, No vs Yes	1.127	0.674	1.884
Preventive Care, No vs Yes	1.119	0.522	2.399
Number of outpatient and virtual visits, 0 vs >=11	0.945	0.156	5.734
Number of outpatient and virtual visits, 1-4 vs >=11	1.002	0.441	2.276
Number of outpatient and virtual visits, 5-10 vs >=11	0.682	0.365	1.276
Obese, No vs Yes	0.633	0.378	1.062
Obese, Unknown vs Yes	0.671	0.175	2.579
Charlson comorbidity score, 0 vs >=2	0.814	0.401	1.653
Charlson comorbidity score, 1 vs >=2	1.259	0.639	2.482
Frailty, Quartile 1 vs Quartile 4	2.186	0.942	5.076
Frailty, Quartile 2 vs Quartile 4	2.095	0.962	4.564
Frailty, Quartile 3 vs Quartile 4	2.14	1.011	4.527
Specimen type, Nasopharyngeal/oropharyngeal swab vs Saliva	1.503	0.771	2.93
Immunocompromised status, No vs Yes	4.096	1.381	12.154
History of COVID-19 diagnosis, No vs Yes	10.522	2.028	54.586

## Supplementary Table 21. Full model for 3-dose VE against delta variant infection (subgroup of female)

Odds Ratio Estimates			
Effect	Point Estimate	95% Wald C	
Vaccination status, Vaccinated vs Unvaccinated	0.056	0.04	0.078
History of SARS-CoV-2 molecular test, No vs Yes	1.411	1.172	1.7
Preventive Care, No vs Yes	1.123	0.94	1.343
Number of outpatient and virtual visits, 0 vs >=11	1.863	1.27	2.732
Number of outpatient and virtual visits, 1-4 vs >=11	1.464	1.173	1.828
Number of outpatient and virtual visits, 5-10 vs >=11	1.33	1.086	1.629
Obese, No vs Yes	0.895	0.76	1.052
Obese, Unknown vs Yes	0.765	0.568	1.031
Charlson comorbidity score, 0 vs >=2	1.004	0.708	1.425
Charlson comorbidity score, 1 vs >=2	1.16	0.796	1.69
Frailty, Quartile 1 vs Quartile 4	1.075	0.837	1.381
Frailty, Quartile 2 vs Quartile 4	0.95	0.73	1.236
Frailty, Quartile 3 vs Quartile 4	1.014	0.8	1.286
Specimen type, Nasopharyngeal/oropharyngeal swab vs Saliva	3.769	3.115	4.56
Immunocompromised status, No vs Yes	1.606	0.97	2.662
History of COVID-19 diagnosis, No vs Yes	7.264	5.311	9.937

## Supplementary Table 22. Full model for 3-dose VE against delta variant infection (subgroup of male)

Odds Ratio Estimates			
Effect	Point Estimate	95% Wald (	Confidence rval
Vaccination status, Vaccinated vs Unvaccinated	0.054	0.037	0.08
History of SARS-CoV-2 molecular test, No vs Yes	1.392	1.171	1.654
Preventive Care, No vs Yes	1.249	1.024	1.524
Number of outpatient and virtual visits, 0 vs >=11	1.141	0.798	1.633
Number of outpatient and virtual visits, 1-4 vs >=11	1.306	0.992	1.72
Number of outpatient and virtual visits, 5-10 vs >=11	0.914	0.699	1.195
Obese, No vs Yes	0.871	0.721	1.052
Obese, Unknown vs Yes	1.027	0.8	1.32
Charlson comorbidity score, 0 vs >=2	0.886	0.608	1.292
Charlson comorbidity score, 1 vs >=2	1.294	0.853	1.964
Frailty, Quartile 1 vs Quartile 4	1.209	0.928	1.575
Frailty, Quartile 2 vs Quartile 4	1.052	0.682	1.623
Frailty, Quartile 3 vs Quartile 4	1.114	0.871	1.423
Specimen type, Nasopharyngeal/oropharyngeal swab vs Saliva	3.54	2.868	4.368
Immunocompromised status, No vs Yes	2.598	1.356	4.979
History of COVID-19 diagnosis, No vs Yes	8.964	6.166	13.032

## Supplementary Table 23. Full model for 3-dose VE against delta variant infection (subgroup of Hispanic)

Odds Ratio Estimates			
Effect	Point Estimate		Confidence rval
Vaccination status, Vaccinated vs Unvaccinated	0.069	0.045	0.106
History of SARS-CoV-2 molecular test, No vs Yes	1.34	1.1	1.633
Preventive Care, No vs Yes	1.215	0.996	1.481
Number of outpatient and virtual visits, 0 vs >=11	1.496	1.009	2.217
Number of outpatient and virtual visits, 1-4 vs >=11	1.47	1.135	1.904
Number of outpatient and virtual visits, 5-10 vs >=11	1.256	0.977	1.614
Obese, No vs Yes	0.972	0.809	1.169
Obese, Unknown vs Yes	1.092	0.826	1.444
Charlson comorbidity score, 0 vs >=2	0.728	0.481	1.101
Charlson comorbidity score, 1 vs >=2	0.875	0.56	1.366
Frailty, Quartile 1 vs Quartile 4	1.096	0.832	1.443
Frailty, Quartile 2 vs Quartile 4	1.038	0.767	1.404
Frailty, Quartile 3 vs Quartile 4	1.161	0.894	1.507
Specimen type, Nasopharyngeal/oropharyngeal swab vs Saliva	4.264	3.377	5.384
Immunocompromised status, No vs Yes	2.077	1.083	3.982
History of COVID-19 diagnosis, No vs Yes	9.321	6.63	13.104

### Supplementary Table 24. Full model for 3-dose VE against delta variant infection (subgroup of Non-Hispanic and others)

History of COVID-19 diagnosis, No vs Yes

#### **Odds Ratio Estimates** 95% Wald Confidence **Effect Point Estimate** Interval Vaccination status, Vaccinated vs Unvaccinated 0.049 0.036 0.068 History of SARS-CoV-2 molecular test, No vs Yes 1.452 1.231 1.712 Preventive Care, No vs Yes 0.958 1.365 1.143 Number of outpatient and virtual visits, 0 vs >=11 1.372 0.967 1.946 Number of outpatient and virtual visits, 1-4 vs >=11 1.323 1.055 1.658 Number of outpatient and virtual visits, 5-10 vs >=11 1.029 0.835 1.269 Obese, No vs Yes 0.805 0.682 0.951 Obese, Unknown vs Yes 0.792 0.611 1.026 Charlson comorbidity score, 0 vs >=2 1.117 0.806 1.549 Charlson comorbidity score, 1 vs >=2 1.515 1.058 2.169 Frailty, Quartile 1 vs Quartile 4 0.949 1.55 1.213 Frailty, Quartile 2 vs Quartile 4 1.075 0.821 1.408 Frailty, Quartile 3 vs Quartile 4 0.998 0.792 1.258 Specimen type, Nasopharyngeal/oropharyngeal swab vs Saliva 2.803 4.003 3.349 Immunocompromised status, No vs Yes 1.863 1.12 3.1

6.581

4.69

9.236

## Supplementary Table 25. Full model for 3-dose VE against delta variant infection (subgroup of immunocompromised population)

	Point	95% Wald	Confidence	
Effect	Estimate		erval	
Vaccination status, Vaccinated vs Unvaccinated	0.294	0.125	0.69	
History of SARS-CoV-2 molecular test, No vs Yes	1.719	0.783	3.774	
Preventive Care, No vs Yes	1.703	0.688	4.213	
Obese, No vs Yes	1.364	0.619	3.003	
Obese, Unknown vs Yes	3.835	0.448	32.845	
Charlson comorbidity score, 0 vs >=2	0.909	0.35	2.364	
Charlson comorbidity score, 1 vs >=2	2.397	0.912	6.297	
Frailty, Quartile 1 vs Quartile 4	2.594	0.884	7.615	
Frailty, Quartile 2 vs Quartile 4	0.856	0.276	2.658	
Frailty, Quartile 3 vs Quartile 4	1.325	0.457	3.839	
Specimen type, Nasopharyngeal/oropharyngeal swab vs Saliva	12.207	2.606	57.185	
History of COVID-19 diagnosis, No vs Yes	7.615	1.512	38.353	
Age group, 18-44 years old vs 75 and older	0.268	0.035	2.052	
Age group, 45-64 years old vs 75 and older	0.355	0.05	2.514	
Age group, 65-74 years old vs 75 and older	0.323	0.043	2.42	
Sex, Female vs Male	1.429	0.667	3.063	
Race/ethnicity, Hispanic vs Other/Unknown	1.22	0.187	7.958	
Race/ethnicity, Non-Hispanic Asian vs Other/Unknown	4.203	0.408	43.27	
Race/ethnicity, Non-Hispanic Black vs Other/Unknown	3.04	0.358	25.813	
Race/ethnicity, Non-Hispanic White vs Other/Unknown	0.778	0.12	5.06	

## Supplementary Table 26. Full model for 3-dose VE against delta variant infection (subgroup of non-immunocompromised)

	Point	0E9/ Wold	Confidence
Effect	Estimate		erval
Vaccination status, Vaccinated vs Unvaccinated	0.063	0.051	0.078
History of SARS-CoV-2 molecular test, No vs Yes	1.387	1.233	1.56
Preventive Care, No vs Yes	1.144	1.011	1.293
Number of outpatient and virtual visits, 0 vs >=11	1.472	1.152	1.882
Number of outpatient and virtual visits, 1-4 vs >=11	1.43	1.221	1.676
Number of outpatient and virtual visits, 5-10 vs >=11	1.192	1.026	1.386
Obese, No vs Yes	0.861	0.768	0.966
Obese, Unknown vs Yes	0.933	0.785	1.11
Charlson comorbidity score, 0 vs >=2	0.936	0.735	1.193
Charlson comorbidity score, 1 vs >=2	1.153	0.886	1.5
Frailty, Quartile 1 vs Quartile 4	1.159	0.979	1.373
Frailty, Quartile 2 vs Quartile 4	1.092	0.904	1.319
Frailty, Quartile 3 vs Quartile 4	1.098	0.935	1.29
Specimen type, Nasopharyngeal/oropharyngeal swab vs Saliva	3.789	3.334	4.306
History of COVID-19 diagnosis, No vs Yes	8.245	6.566	10.352
Age group, 18-44 years old vs 75 and older	0.292	0.184	0.464
Age group, 45-64 years old vs 75 and older	0.397	0.251	0.626
Age group, 65-74 years old vs 75 and older	0.752	0.462	1.222
Sex, Female vs Male	1.262	1.133	1.406
Race/ethnicity, Hispanic vs Other/Unknown	0.97	0.798	1.178
Race/ethnicity, Non-Hispanic Asian vs Other/Unknown	1.969	1.411	2.747
Race/ethnicity, Non-Hispanic Black vs Other/Unknown	0.881	0.673	1.153
Race/ethnicity, Non-Hispanic White vs Other/Unknown	1.073	0.881	1.307

## Supplementary Table 27. Full model for 3-dose VE against omicron variant infection (subgroup of age<65)

	Point	95% Wald	Confidence
Effect	Estimate	Inte	rval
Vaccination status, Vaccinated vs Unvaccinated	0.291	0.271	0.311
History of SARS-CoV-2 molecular test, No vs Yes	0.9	0.847	0.957
Preventive Care, No vs Yes	1.08	1.016	1.149
Number of outpatient and virtual visits, 0 vs >=11	1.595	1.404	1.813
Number of outpatient and virtual visits, 1-4 vs >=11	1.417	1.311	1.531
Number of outpatient and virtual visits, 5-10 vs >=11	1.267	1.181	1.36
Obese, No vs Yes	1.033	0.976	1.093
Obese, Unknown vs Yes	0.991	0.906	1.084
Charlson comorbidity score, 0 vs >=2	1.127	0.992	1.281
Charlson comorbidity score, 1 vs >=2	1.038	0.903	1.193
Frailty, Quartile 1 vs Quartile 4	1.037	0.956	1.124
Frailty, Quartile 2 vs Quartile 4	1.056	0.965	1.155
Frailty, Quartile 3 vs Quartile 4	1.051	0.973	1.135
Specimen type, Nasopharyngeal/oropharyngeal swab vs Saliva	1.701	1.59	1.819
Immunocompromised status, No vs Yes	1.063	0.899	1.258
History of COVID-19 diagnosis, No vs Yes	1.491	1.391	1.599

## Supplementary Table 28. Full model for 3-dose VE against omicron variant infection (subgroup of age≥65)

	Point	95% Wald (	Confidence
Effect	Estimate	Inte	rval
Vaccination status, Vaccinated vs Unvaccinated	0.357	0.283	0.45
History of SARS-CoV-2 molecular test, No vs Yes	1.117	0.931	1.341
Preventive Care, No vs Yes	0.793	0.573	1.098
Number of outpatient and virtual visits, 0 vs >=11	0.765	0.327	1.787
Number of outpatient and virtual visits, 1-4 vs >=11	1.089	0.783	1.515
Number of outpatient and virtual visits, 5-10 vs >=11	0.849	0.689	1.045
Obese, No vs Yes	0.869	0.727	1.04
Obese, Unknown vs Yes	0.732	0.432	1.238
Charlson comorbidity score, 0 vs >=2	1.147	0.911	1.444
Charlson comorbidity score, 1 vs >=2	1.034	0.827	1.294
Frailty, Quartile 1 vs Quartile 4	1.061	0.794	1.417
Frailty, Quartile 2 vs Quartile 4	1.076	0.834	1.389
Frailty, Quartile 3 vs Quartile 4	1.04	0.819	1.319
Specimen type, Nasopharyngeal/oropharyngeal swab vs Saliva	1.316	1.055	1.641
Immunocompromised status, No vs Yes	1.232	0.868	1.75
History of COVID-19 diagnosis, No vs Yes	1.136	0.827	1.56

### Supplementary Table 29. Full model for 3-dose VE against omicron variant infection (subgroup of female)

Odds Ratio Estimates			
Effect	Point Estimate	95% Wald C Inter	
Vaccination status, Vaccinated vs Unvaccinated	0.3	0.276	0.326
History of SARS-CoV-2 molecular test, No vs Yes	0.871	0.805	0.944
Preventive Care, No vs Yes	1.006	0.928	1.09
Number of outpatient and virtual visits, 0 vs >=11	1.556	1.294	1.87
Number of outpatient and virtual visits, 1-4 vs >=11	1.5	1.363	1.651
Number of outpatient and virtual visits, 5-10 vs >=11	1.251	1.151	1.359
Obese, No vs Yes	1.043	0.973	1.119
Obese, Unknown vs Yes	0.996	0.874	1.135
Charlson comorbidity score, 0 vs >=2	1.119	0.967	1.295
Charlson comorbidity score, 1 vs >=2	1.036	0.887	1.21
Frailty, Quartile 1 vs Quartile 4	0.991	0.89	1.102
Frailty, Quartile 2 vs Quartile 4	1.012	0.908	1.128
Frailty, Quartile 3 vs Quartile 4	1.096	0.994	1.209
Specimen type, Nasopharyngeal/oropharyngeal swab vs Saliva	1.578	1.45	1.716
Immunocompromised status, No vs Yes	1.204	0.986	1.472
History of COVID-19 diagnosis, No vs Yes	1.462	1.338	1.597

## Supplementary Table 30. Full model for 3-dose VE against omicron variant infection (subgroup of male)

Odds Ratio Estimates			
Effect	Point Estimate	95% Wald C	
Vaccination status, Vaccinated vs Unvaccinated	0.3	0.271	0.334
History of SARS-CoV-2 molecular test, No vs Yes	0.975	0.895	1.061
Preventive Care, No vs Yes	1.165	1.061	1.279
Number of outpatient and virtual visits, 0 vs >=11	1.43	1.191	1.716
Number of outpatient and virtual visits, 1-4 vs >=11	1.245	1.101	1.407
Number of outpatient and virtual visits, 5-10 vs >=11	1.156	1.032	1.295
Obese, No vs Yes	0.978	0.898	1.066
Obese, Unknown vs Yes	0.946	0.839	1.068
Charlson comorbidity score, 0 vs >=2	1.093	0.932	1.282
Charlson comorbidity score, 1 vs >=2	0.983	0.827	1.169
Frailty, Quartile 1 vs Quartile 4	1.113	0.986	1.256
Frailty, Quartile 2 vs Quartile 4	1.111	0.966	1.278
Frailty, Quartile 3 vs Quartile 4	1.017	0.906	1.142
Specimen type, Nasopharyngeal/oropharyngeal swab vs Saliva	1.78	1.612	1.966
Immunocompromised status, No vs Yes	0.978	0.776	1.233
History of COVID-19 diagnosis, No vs Yes	1.476	1.328	1.641

## Supplementary Table 31. Full model for 3-dose VE against omicron variant infection (subgroup of Hispanic)

Odds Ratio Estimates			
Effect	Point Estimate	95% Wald ( Inte	
Vaccination status, Vaccinated vs Unvaccinated	0.32	0.29	0.354
History of SARS-CoV-2 molecular test, No vs Yes	0.844	0.772	0.922
Preventive Care, No vs Yes	1.078	0.989	1.176
Number of outpatient and virtual visits, 0 vs >=11	1.615	1.35	1.932
Number of outpatient and virtual visits, 1-4 vs >=11	1.405	1.26	1.567
Number of outpatient and virtual visits, 5-10 vs >=11	1.228	1.112	1.356
Obese, No vs Yes	1.009	0.933	1.09
Obese, Unknown vs Yes	1.045	0.919	1.188
Charlson comorbidity score, 0 vs >=2	1.112	0.943	1.31
Charlson comorbidity score, 1 vs >=2	1.081	0.908	1.287
Frailty, Quartile 1 vs Quartile 4	1.027	0.914	1.153
Frailty, Quartile 2 vs Quartile 4	1.031	0.909	1.169
Frailty, Quartile 3 vs Quartile 4	1.134	1.016	1.265
Specimen type, Nasopharyngeal/oropharyngeal swab vs Saliva	1.655	1.496	1.83
Immunocompromised status, No vs Yes	1.067	0.847	1.343
History of COVID-19 diagnosis, No vs Yes	1.549	1.415	1.696

# Supplementary Table 32. Full model for 3-dose VE against omicron variant infection (subgroup of Non-Hispanic and others)

Odds Ratio Estimates			
Effect	Point Estimate	95% ' Confidenc	
Vaccination status, Vaccinated vs Unvaccinated	0.286	0.262	0.312
History of SARS-CoV-2 molecular test, No vs Yes	0.978	0.905	1.056
Preventive Care, No vs Yes	1.067	0.981	1.161
Number of outpatient and virtual visits, 0 vs >=11	1.519	1.281	1.802
Number of outpatient and virtual visits, 1-4 vs >=11	1.35	1.218	1.496
Number of outpatient and virtual visits, 5-10 vs >=11	1.187	1.085	1.299
Obese, No vs Yes	1.025	0.95	1.106
Obese, Unknown vs Yes	0.933	0.826	1.053
Charlson comorbidity score, 0 vs >=2	1.075	0.933	1.239
Charlson comorbidity score, 1 vs >=2	0.939	0.805	1.096
Frailty, Quartile 1 vs Quartile 4	1.093	0.979	1.22
Frailty, Quartile 2 vs Quartile 4	1.092	0.97	1.231
Frailty, Quartile 3 vs Quartile 4	1.074	0.97	1.189
Specimen type, Nasopharyngeal/oropharyngeal swab vs Saliva	1.666	1.532	1.811
Immunocompromised status, No vs Yes	1.131	0.925	1.382
History of COVID-19 diagnosis, No vs Yes	1.379	1.245	1.528

## Supplementary Table 33. Full model for 3-dose VE against omicron variant infection (subgroup of immunocompromised population)

	D-1-4	050/ 14/-1-1	<b></b>
Effect	Point Estimate	95% Wald (	
Vaccination status, Vaccinated vs Unvaccinated	0.706	0.5	0.997
History of SARS-CoV-2 molecular test, No vs Yes	1.271	0.899	1.798
Preventive Care, No vs Yes	1.62	1.088	2.414
Number of outpatient and virtual visits, 0 vs >=11	0.538	0.097	2.983
Number of outpatient and virtual visits, 1-4 vs >=11	1.174	0.644	2.141
Number of outpatient and virtual visits, 5-10 vs >=11	1.407	0.967	2.046
Obese, No vs Yes	0.947	0.703	1.275
Obese, Unknown vs Yes	0.732	0.256	2.095
Charlson comorbidity score, 0 vs >=2	1.03	0.708	1.501
Charlson comorbidity score, 1 vs >=2	0.853	0.561	1.297
Frailty, Quartile 1 vs Quartile 4	1.15	0.711	1.859
Frailty, Quartile 2 vs Quartile 4	1.336	0.857	2.082
Frailty, Quartile 3 vs Quartile 4	1.316	0.868	1.996
Specimen type, Nasopharyngeal/oropharyngeal swab vs Saliva	1.161	0.796	1.693
History of COVID-19 diagnosis, No vs Yes	1.413	0.91	2.193
Age group, 18-44 years old vs 75 and older	0.595	0.309	1.145
Age group, 45-64 years old vs 75 and older	0.902	0.482	1.688
Age group, 65-74 years old vs 75 and older	1.27	0.629	2.563
Sex, Female vs Male	1.033	0.764	1.396
Race/ethnicity, Hispanic vs Other/Unknown	1.122	0.542	2.319
Race/ethnicity, Non-Hispanic Asian vs Other/Unknown	1.021	0.422	2.471
Race/ethnicity, Non-Hispanic Black vs Other/Unknown	1.083	0.488	2.402
Race/ethnicity, Non-Hispanic White vs Other/Unknown	1.019	0.488	2.13

### Supplementary Table 34. Full model for 3-dose VE against omicron variant infection (subgroup of non-immunocompromised)

#### **Odds Ratio Estimates Point** 95% Wald Confidence **Effect Estimate** Interval Vaccination status, Vaccinated vs Unvaccinated 0.295 0.276 0.314 History of SARS-CoV-2 molecular test, No vs Yes 0.908 0.857 0.963 1.005 Preventive Care, No vs Yes 1.068 1.134 Number of outpatient and virtual visits, 0 vs >=11 1.57 1.389 1.774 Number of outpatient and virtual visits, 1-4 vs >=11 1.378 1.28 1.484 Number of outpatient and virtual visits, 5-10 vs >=11 1.294 1.21 1.132 Obese, No vs Yes 1.015 0.962 1.071 Obese, Unknown vs Yes 0.978 0.897 1.066 Charlson comorbidity score, 0 vs >=2 1.116 0.999 1.247 Charlson comorbidity score, 1 vs >=2 1.03 0.914 1.16 Frailty, Quartile 1 vs Quartile 4 1.064 0.984 1.151 Frailty, Quartile 2 vs Quartile 4 1.063 0.975 1.16 Frailty, Quartile 3 vs Quartile 4 1.087 1.01 1.17 Specimen type, Nasopharyngeal/oropharyngeal swab vs Saliva 1.817 1.705 1.6 History of COVID-19 diagnosis, No vs Yes 1.478 1.382 1.581 Age group, 18-44 years old vs 75 and older 0.37 0.307 0.445 0.439 0.632 Age group, 45-64 years old vs 75 and older 0.526 Age group, 65-74 years old vs 75 and older 0.832 0.685 1.009 Sex, Female vs Male 1.141 1.084 1.2 Race/ethnicity, Hispanic vs Other/Unknown 0.968 0.882 1.063 Race/ethnicity, Non-Hispanic Asian vs Other/Unknown 1.472 1.297 1.67 Race/ethnicity, Non-Hispanic Black vs Other/Unknown 0.931 0.83 1.044 Race/ethnicity, Non-Hispanic White vs Other/Unknown 1.015 0.921 1.119

## Supplementary Table 35. Full model for 3-dose VE against omicron variant infection among individuals without COVID-19 history, age<65

	Point	95% Wald (	onfidence
Effect	Estimate	Interval	
Vaccination status, Vaccinated vs Unvaccinated	0.299	0.279	0.32
History of SARS-CoV-2 molecular test, No vs Yes	0.898	0.844	0.955
Preventive Care, No vs Yes	1.087	1.016	1.163
Number of outpatient and virtual visits, 0 vs >=11	1.577	1.373	1.81
Number of outpatient and virtual visits, 1-4 vs >=11	1.439	1.323	1.566
Number of outpatient and virtual visits, 5-10 vs >=11	1.28	1.185	1.382
Obese, No vs Yes	1.026	0.965	1.092
Obese, Unknown vs Yes	0.974	0.885	1.072
Charlson comorbidity score, 0 vs >=2	1.151	1.003	1.322
Charlson comorbidity score, 1 vs >=2	1.049	0.901	1.22
Frailty, Quartile 1 vs Quartile 4	1.032	0.946	1.126
Frailty, Quartile 2 vs Quartile 4	1.062	0.962	1.172
Frailty, Quartile 3 vs Quartile 4	1.052	0.968	1.142
Specimen type, Nasopharyngeal/oropharyngeal swab vs Saliva	1.727	1.607	1.855
Immunocompromised status, No vs Yes	1.035	0.865	1.239
Age Group, 18-44 years old vs 45-64 years old	0.697	0.653	0.744
Sex, Female vs Male	1.144	1.079	1.212
Race/ethnicity, Hispanic vs Other/Unknown	0.98	0.885	1.085
Race/ethnicity, Non-Hispanic Asian vs Other/Unknown	1.475	1.285	1.694
Race/ethnicity, Non-Hispanic Black vs Other/Unknown	0.927	0.816	1.052
Race/ethnicity, Non-Hispanic White vs Other/Unknown	1.027	0.923	1.143

## Supplementary Table 36. Full model for 3-dose VE against omicron variant infection among individuals without COVID-19 history, age≥65

Effect	Point Estimate	95% Wald Confidence Interval	
History of SARS-CoV-2 molecular test, No vs Yes	1.14	0.95	1.368
Preventive Care, No vs Yes	0.791	0.564	1.109
Number of outpatient and virtual visits, 0 vs >=11	0.774	0.326	1.842
Number of outpatient and virtual visits, 1-4 vs >=11	1.034	0.738	1.449
Number of outpatient and virtual visits, 5-10 vs >=11	0.864	0.699	1.069
Obese, No vs Yes	0.836	0.695	1.006
Obese, Unknown vs Yes	0.715	0.417	1.226
Charlson comorbidity score, 0 vs >=2	1.182	0.933	1.497
Charlson comorbidity score, 1 vs >=2	1.001	0.794	1.262
Frailty, Quartile 1 vs Quartile 4	1.009	0.748	1.362
Frailty, Quartile 2 vs Quartile 4	1.082	0.833	1.405
Frailty, Quartile 3 vs Quartile 4	1.029	0.806	1.316
Specimen type, Nasopharyngeal/oropharyngeal swab vs Saliva	1.33	1.061	1.669
Immunocompromised status, No vs Yes	1.149	0.802	1.646
Age group, 65-74 years old vs 75 and older	0.846	0.694	1.031
Sex, Female vs Male	0.945	0.795	1.124
Race/ethnicity, Hispanic vs Other/Unknown	0.996	0.588	1.688
Race/ethnicity, Non-Hispanic Asian vs Other/Unknown	1.037	0.59	1.823
Race/ethnicity, Non-Hispanic Black vs Other/Unknown	0.899	0.511	1.58
Race/ethnicity, Non-Hispanic White vs Other/Unknown	0.952	0.566	1.6